Document Detail


Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.
MedLine Citation:
PMID:  19436667     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Approximately 25% of the adult population worldwide is hypertensive and thus at risk of cardiovascular morbidity and mortality. Despite the availability of many antihypertensive drugs, at least 50% of patients do not achieve blood pressure (BP) targets and thus remain at increased cardiovascular risk. Fixed-dose (FD) irbesartan/hydrochlorothiazide (HCTZ) is an antihypertensive combination therapy approved for the treatment of patients whose BP is not adequately controlled on monotherapy and for initial treatment of patients likely to need multiple drugs to achieve their BP goal. The efficacy and tolerability of FD irbesartan/HCTZ has been demonstrated in both patient populations in large multicenter studies. In patients failing antihypertensive monotherapy, FD irbesartan/HCTZ (150/12.5 mg) has been shown to be more effective than FD valsartan/HCTZ (80/12.5 mg) and at least comparable to FD losartan/HCTZ (50/12.5 mg). In patients with moderate or severe hypertension receiving FD irbesartan/HCTZ as initial therapy, this combination achieved more rapid BP reductions compared with irbesartan monotherapy and enabled a greater proportion of patients with severe hypertension to achieve their BP target. FD irbesartan/HCTZ is thus a valuable addition to the clinician's armamentarium for the management of hypertension and should help more patients achieve their BP target.
Authors:
Peter Bramlage
Related Documents :
7173927 - The problem of psilocybin mushroom abuse.
2398267 - Gastric mucosal prostaglandin e2 levels in cirrhosis and portal hypertension.
2687427 - Use of salt substitutes in the treatment of diuretic-induced hypokalemia.
16621877 - A history of arterial hypertension does not affect mortality in patients hospitalised w...
15359997 - Hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: a single...
10623367 - Costs associated with symptomatic systolic heart failure.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2009-04-08
Journal Detail:
Title:  Vascular health and risk management     Volume:  5     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2009  
Date Detail:
Created Date:  2009-05-13     Completed Date:  2009-06-19     Revised Date:  2013-06-02    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  213-24     Citation Subset:  IM    
Affiliation:
Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany. peter.bramlage@ikpe.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / adverse effects,  pharmacokinetics,  therapeutic use*
Antihypertensive Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Biphenyl Compounds / adverse effects,  pharmacokinetics,  therapeutic use*
Blood Pressure / drug effects
Diuretics / adverse effects,  pharmacokinetics,  therapeutic use*
Drug Combinations
Humans
Hydrochlorothiazide / adverse effects,  pharmacokinetics,  therapeutic use*
Hypertension / drug therapy*,  physiopathology
Tetrazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Diuretics; 0/Drug Combinations; 0/Tetrazoles; 138402-11-6/irbesartan; 58-93-5/Hydrochlorothiazide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended ...
Next Document:  Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a histor...